EARLY UPREGULATION OF MATRIX METALLOPROTEINASES
FOLLOWING REPERFUSION TRIGGERS NEUROINFLAMMATORY
MEDIATORS IN BRAIN ISCHEMIA IN RAT
Diana Amantea,* Rossella Russo,* Micaela Gliozzi,y Vincenza Fratto,y
Laura Berliocchi,*,z G. Bagetta,* G. Bernardi,} and M. Tiziana Corasanitiy,z
*Department of Pharmacobiology, UCHAD Section of Neuropharmacology of Normal
and Pathological Neuronal Plasticity, University of Calabria, 87036 Rende, Italy
y
Department of Pharmacobiological Sciences, Faculty of Pharmacy, University
‘‘Magna Graecia’’ of Catanzaro, 88100 Catanzaro, Italy
z
Mondino-Tor Vergata Center for Experimental Neuropharmacology, University of Rome Tor
Vergata, 00133 Rome, Italy
}
CERC-Fondazione S. Lucia IRCCS, University of Rome Tor Vergata, 00133 Rome, Italy
I. Introduction
II. Methods
A. Focal Cerebral Ischemia and Drug Treatments
B. Neuropathology and Quantification of Ischemic Damage
C. IL-1 ELISA
D. Western Blotting
E. In Situ Zymography
F. Gel Zymography
G. Fluorimetric Caspase-1 Activity Assay
H. Statistical Analysis
III. Results
IV. Discussion
References
Abnormal expression of matrix metalloproteinases (MMPs) has been implicated in the pathophysiology of neuroinflammatory processes that accompany
most central nervous system disease. In particular, early upregulation of the
gelatinases MMP-2 and MMP-9 has been shown to contribute to disruption of
the blood–brain barrier and to death of neurons in ischemic stroke. In situ zymography reveals a significant increase in gelatinolytic MMPs activity in the ischemic
brain hemisphere after 2-h middle cerebral artery occlusion (MCAo) followed by
2-h reperfusion in rat. Accordingly, gel zymography demonstrates that expression
and activity of MMP-2 and MMP-9 are enhanced in cortex and striatum ipsilateral
to the ischemic insult. The latter eVect appears to be instrumental for development
INTERNATIONAL REVIEW OF
NEUROBIOLOGY, VOL. 82
DOI: 10.1016/S0074-7742(07)82008-3
149
Copyright 2007, Elsevier Inc.
All rights reserved.
0074-7742/07 $35.00
150
AMANTEA et al.
of delayed brain damage since administration of a broad spectrum, highly specific
MMPs inhibitor, GM6001, but not by its negative control, results in a significant
(50%) reduction in ischemic brain volume. Increased gelatinase activity in the
ischemic cortex coincides with elevation (166% vs sham) of mature interleukin-1
(IL-1) after 2-h reperfusion and this does not appear to implicate a caspase-1dependent processing of pro(31 kDa)-IL-1 to yield mature (17 kDa) IL-1. More
importantly, when administered at a neuroprotective dose GM6001 abolishes the
early IL-1 increase in the ischemic cortex and reduces the cleavage of the cytokine
proform supporting the deduction that MMPs may initiate IL-1 processing.
In conclusion, development of tissue damage that follows transient ischemia
implicates a crucial interplay between MMPs and mediators of neuroinflammation (e.g., IL-1), and this further underscores the therapeutic potential of MMPs
inhibitors in the treatment of stroke.
I. Introduction
Interleukin-1 (IL-1) is a proinflammatory cytokine that has been identified
as an important mediator of neurodegeneration induced by excitatory or
traumatic brain injury and, most notably, by experimental cerebral ischemia in
rodents (Rothwell, 2003). Induction of IL-1 mRNA has been shown in rats
following either permanent (Buttini et al., 1994; Liu et al., 1993) or transient (Wang
et al., 1994) middle cerebral artery occlusion (MCAo). Accordingly, IL-1 protein
increases very early following permanent MCAo (Davies et al., 1999; Legos et al.,
2000) and peaks within hours of reperfusion in transient focal ischemic models in
rodents (Hara et al., 1997b; Zhang et al., 1998). Intracerebral injection of neutralizing anti-IL-1 antibody to rats reduces ischemic brain damage (Yamasaki
et al., 1995) and both intracerebroventricular and systemic administration of
IL-1receptor antagonist (IL-1ra) markedly reduce brain damage induced by
focal stroke, further implicating IL-1 in ischemic pathophysiology (Garcia
et al., 1995; Mulcahy et al., 2003; Relton and Rothwell, 1992; Relton et al., 1996).
IL-1 is synthesized as a precursor molecule, pro-IL-1, which is cleaved
and converted into the mature, biologically active, form of the cytokine by
caspase-1, formerly referred to as interleukin-1 converting enzyme (ICE; Black
et al., 1988; Howard et al., 1991; Thornberry et al., 1992). Inhibition of caspase-1 by
Ac-YVAD-cmk aVords neuroprotection in rodent models of permanent (RabuVetti
et al., 2000) or transient (Hara et al., 1997b) MCAo (tMCAo), and evidence
from knockout mice indicates that caspase-1 is important in the development of
cerebral ischemic damage (Friedlander and Yuan, 1998; Schielke et al., 1998).
MMPS MODULATE IL-1 PRODUCTION IN BRAIN ISCHEMIA
151
However, to date, it is not clear whether neuroprotection yielded by caspase-1
preferring inhibitors is mediated by reduced IL-1 production or by interference
with the death process.
Although in vitro studies have clearly established the role of ICE in the maturation
of IL-1, evidence from ICE-deficient mice suggests that cytokine activation might
also involve other mechanisms (Fantuzzi et al., 1997). Matrix metalloproteinases
(MMPs) have been suggested to contribute to the biological processing of IL-1 as
they have been shown to be involved in both the maturation and inactivation of the
cytokine in vitro (Ito et al., 1996; Schönbeck et al., 1998).
MMPs are zinc-dependent endopeptidases, classically recognized as matrixdegrading enzymes implicated in tissue remodeling during development, wound
healing, and angiogenesis. MMPs are expressed as zymogens that are activated on
disruption of the zinc–thiol interaction between the catalytic site and the prodomain.
MMPs cleave protein components of the extracellular matrix (ECM) such as
collagen, proteoglycan, and laminin, but also process a number of cell surface and
soluble proteins including receptors, cytokines, and chemokines (Sternlicht and
Werb, 2001). In addition to their physiological roles, MMPs are markedly upregulated in the central nervous system (CNS) in response to injury and have been
implicated in the propagation and regulation of neuroinflammatory processes
that accompany most CNS disease (Cunningham et al., 2005; Rosenberg, 2002).
Evidence suggests that abnormal MMP activity plays a role in the pathophysiology
of cerebral ischemia. In particular, the gelatinases MMP-2 and MMP-9 become
activated following focal brain ischemia and participate to the disruption of
the blood–brain barrier (BBB) and hemorrhagic transformation following injury
both in animal models (Asahi et al., 2000; Heo et al., 1999; Romanic et al., 1998;
Rosenberg et al., 1998) and stroke patients (Horstmann et al., 2003; Rosell et al.,
2006). Treatment with MMP inhibitors or MMP neutralizing antibodies has been
shown to decrease infarct volume and prevent BBB disruption after permanent and
tMCAo in rodents (Asahi et al., 2000; Gasche et al., 2001; Romanic et al., 1998).
MMP-9, but not MMP-2 (Asahi et al., 2001a), gene knockout is associated with
reduced infarct size and less BBB damage in mouse models of ischemic stroke (Asahi
et al., 2000, 2001b). This large body of evidence suggests that MMPs and, most
notably, the gelatinases MMP-2 and MMP-9 might contribute to the development
of ischemic brain damage, though the underlying mechanisms need to be discovered. Various studies have emphasized the role of MMPs and their endogenous
inhibitors (TIMPs) in the regulation of neuronal cell death through the modulation
of excitotoxicity (Jourquin et al., 2003), anoikis (Gu et al., 2002), calpain activity
(Copin et al., 2005), death receptor activation (Wetzel et al., 2003), neurotrophic
factor bioavailability (Lee et al., 2001), and production of neurotoxic products
(Gu et al., 2002; Zhang et al., 2003a). This suggests that, in addition to ECM
degradation, MMPs might elicit some direct, pathogenic eVects, which contribute
to brain tissue damage under various neuropathological conditions.
152
AMANTEA et al.
Here, we suggest that cytokine maturation may represent a likely mechanism
by which MMPs contribute to ischemic neuronal death and postulate that MMPs
might be involved in the early increase of IL-1 occurring following tMCAo in
rat. In fact, increased gelatinolytic, namely, MMP-2 and MMP-9, activity is
observed as early as 2 h following reperfusion, and this is coincident with a
significant increase of IL-1 levels in the ischemic cortex. More interestingly,
pharmacological inhibition of gelatinolytic activity prevents elevation of cortical
IL-1 levels and results in significant neuroprotection.
II. Methods
A. FOCAL CEREBRAL ISCHEMIA AND DRUG TREATMENTS
Adult male Wistar rats (Charles River, Calco, Como, Italy) were housed under
controlled environmental conditions with ambient temperature of 22 C, relative
humidity of 65%, and 12-h light:12-h dark cycle, with free access to food and water.
Brain ischemia was induced by MCAo in rats weighing 280–320 g by intraluminal filament, using the relatively noninvasive technique previously described by
Longa et al. (1989). Briefly, rats were anesthetized with 5% isoflurane in air and were
maintained with the lowest acceptable concentration of the anesthetic (1.5–2%).
Body temperature was measured with a rectal probe and was kept at 37 C during
the surgical procedure with a heating pad. Under an operating microscope, the
external and internal right carotid arteries were exposed through a neck incision.
The external carotid artery was cut approximately 3 mm above the common carotid
artery (CCA) bifurcation and a silk suture was tied loosely around the external
carotid stump. A silicone-coated nylon filament (diameter, 0.28 mm) was then
inserted into the external carotid artery and gently advanced into the internal carotid
artery, approximately 18 mm from the carotid bifurcation, until mild resistance was
felt, thereby indicating occlusion of the origin of the middle cerebral artery in the
Willis circle. The silk suture was tightened around the intraluminal filament to
prevent bleeding. The wound was then sutured and anesthesia discontinued.
Sham rats were exposed to the same surgical procedure without occlusion of MCA.
To allow reperfusion, rats were briefly reanesthetized with isoflurane, and the
nylon filament was withdrawn 2 h after MCAo. After the discontinuation of
isoflurane and wound closure, the animals were allowed to awake and were
kept in their cages with free access to food and water.
N-[(2R)-2-(Hydroxamidocarbonylmethyl)-4-methylpenthanoyl]-L-tryptophan
methylamide (GM6001; also known as Galardin), a potent broad-range inhibitor of
MMPs (Levy et al., 1998), and its negative control (N-t-butoxycarbonyl-L-leucyl-Ltryptophan methylamide, GM6001 negative control), obtained from Calbiochem
(La Jolla, CA), were dissolved in DMSO and administered in a volume of 2 l
through the external carotid artery (i.a.), 15 min prior to MCAo.
MMPS MODULATE IL-1 PRODUCTION IN BRAIN ISCHEMIA
153
All the experimental procedures were in accordance to the guidelines of the
European Community Council Directive 86/609, included in the D.M. 116/
1992 of the Italian Ministry of Health.
B. NEUROPATHOLOGY AND QUANTIFICATION OF ISCHEMIC DAMAGE
Cerebral infarct volume was evaluated 22 h after reperfusion in rats subjected
to 2-h MCAo. Rats were sacrificed by decapitation and the brains were rapidly
removed. Eight serial sections from each brain were cut at 2-mm intervals from
the frontal pole using a rat brain matrix (Harvard Apparatus, Massachusetts). To
measure ischemic damage, brain slices were stained in a solution containing 2%
2,3,5-triphenyltetrazolium chloride (TTC) in saline, at 37 C. After 10-min incubation, the slices were transferred to 10% neutral buVered formaldehyde and
stored at 4 C prior to analysis. Images of TTC-stained sections were captured
using a digital scanner and analyzed using an image analysis software (ImageJ,
version 1.30). The infarct volume (mm3) was calculated by summing the infarcted
area (unstained) of the eight sections and multiplying by the interval thickness
between sections as previously described (Li et al., 2000).
C. IL-1 ELISA
Immunoreactive IL-1 levels were analyzed in individual brain cortical tissue
homogenates by an established, rat-specific, sandwich ELISA previously described
(Corasaniti et al., 2001; Hagan et al.,1996), using an immunoaYnity-purified polyclonal sheep anti-rat IL-1-coating antibody (1 g/ml) and a biotinylated,
immunoaYnity-purified polyclonal sheep anti-rat IL-1-detecting antibody
(1:1000 dilution), kindly provided by Dr. Stephen Poole (National Institute of
Biological Standards and Controls, NIBSC, Hertfordshire, United Kingdom).
Poly-horseradish peroxidase-conjugated streptavidin (CLB, Amsterdam, the
Netherlands) was used at 1:5000 dilution and the color was developed by using the
chromogen o-phenylenediamine. Optical densities (OD) were read at 492 nm by
using an automated plate reader (Multiscan MS, Labsystems, Helsinki, Finland) and
cytokine levels were calculated by interpolation from a standard curve obtained
from recombinant rat IL-1 (0.0–1000 pg/ml). Data were corrected for protein
concentration and the results expressed as picogram of IL-1 per milligram of
protein.
D. WESTERN BLOTTING
For Western blotting analysis of mature and pro-IL-1 immunoreactivities,
20 g of proteins, from the same aliquots used for ELISA assay, were resolved by
15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE),
154
AMANTEA et al.
transferred to nitrocellulose membranes (Optitran BA-S 83, Schleicher & Schuell
Bioscience, Dassel, Germany), and probed overnight at 4 C with a polyclonal
sheep anti-rat antibody, which recognizes both the precursor and mature forms of
this cytokine (S1002/BM, NIBSC; 7.5 g/ml). The membranes were then incubated with horseradish peroxidase-conjugated anti-sheep IgG (1:5000 dilution;
Chemicon International, Inc., Temecula, CA) for 1 h at room temperature.
Immunoreactivity was visualized by chemiluminescent detection (Amersham
Biosciences, GE Healthcare, Milan, Italy).
E. IN SITU ZYMOGRAPHY
In situ zymography with the MMP fluorogenic substrate DQ-gelatin-FITC
(Molecular Probes, Eugene, OR) was performed on OCT-embedded fresh brain
cryostat-cut sections obtained from rat sacrificed after 2-h MCAo followed by 2-h
reperfusion, as previously described (Gu et al., 2002). Briefly, rat brains were dissected out, immediately embedded in OCT (Tissue-Tek, Pennsylvania) and frozen on
dry ice; 15-m-thick coronal sections were cut using a cryostat, air-dried for 1 h at
room temperature, then rehydrated in PBS, and incubated overnight at 37 C with
the quenched fluorogenic substrate DQ-gelatin-FITC (40 g/ml in PBS). The
excess of fluorogenic substrate was washed out by three washing steps, 5 min each,
in PBS. Sections were fixed with 2% paraformaldehyde in PBS for 5 min and
nuclei counterstained with propidium iodide (0.5 g/ml) for 20 min at room temperature. Mounted slides were examined by confocal microscopy to detect the green
fluorescence due to gelatinolytic activity.
F. GEL ZYMOGRAPHY
MMP-2 (gelatinase A) and MMP-9 (gelatinase B) gelatinolytic activities were
detected by gelatin gel zymography (Gu et al., 2005). Individual brain striatal,
cortical, and hippocampal tissue samples (n ¼ 3 per experimental group)
were homogenized in ice-cold Tris-buVered saline (TBS), containing 150-mM
NaCl, 5-mM CaCl2, 0.05% Brij35, pH 7.6, 0.02% NaN3, 1% Triton X-100,
100-M PMSF, and a protease inhibitor cocktail (Sigma, Milan), and centrifuged
at 14,000 g for 20 min at 4 C. Supernatants were subjected to aYnity precipitation with gelatin-conjugated Sepharose beads (Gelatine-Sepharose 4B, Amersham
Biosciences, GE Healthcare, Milan, Italy), overnight at 4 C. The bound proteins
were eluted from the beads in TBS containing 10% DMSO by shaking for 1 h
at 4 C. Ten microliters of extracted brain samples were diluted (1:1) in a nonreducing loading buVer (0.0625-M Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 0.25%
bromophenol blue) and subjected to electrophoresis through a 10% SDS
MMPS MODULATE IL-1 PRODUCTION IN BRAIN ISCHEMIA
155
polyacrylamide gel copolymerized with 0.1% gelatin. After electrophoretic separation, the gel was incubated (2 30 min) in 2.5% Triton X-100 to remove SDS,
washed two times, 15 min each, with water and then incubated for 40 h at 37 C in a
developing buVer containing 50-mM Tris–HCl, pH 7.78; 10-mM CaCl2 and 0.02%
NaN3. Following incubation, the gel was stained for 1 h with 0.25% Coomassie
Brilliant Blue R-250 diluted with methanol (50%) and acetic acid (10%) and finally
destained in a solution of acetic acid:methanol:water (1:3:6). Enzyme activity attributed to MMP-2 and MMP-9 was visualized (on the basis of molecular weight) in the
gelatin-containing zymograms as clear bands against a blue background.
G. FLUORIMETRIC CASPASE-1 ACTIVITY ASSAY
Individual brain cortical tissue samples (n ¼ 4 per experimental group) were
rapidly dissected out and homogenized in ice-cold lysis buVer (50-mM HEPES,
pH 7.4, 150-mM NaCl, 5-mM MgCl2, 5-mM EDTA, 0.1% CHAPS, 5-mM
DTT, 10 g/ml pepstatin A, 10-g/ml leupeptin, 10-g/ml aprotinin); following
10 min incubation on ice, samples were centrifuged at 12,000 g for 10 min
at 4 C and protein concentration in supernatants was determined by the
DC protein assay (Bio-Rad Laboratories, Milan, Italy). Brain cortical supernatants were diluted in assay buVer (100-mM HEPES, pH 7.4, 5-mM EDTA, 0.1%
CHAPS, 5-mM dithiothreitol, 10% glycerol) to a final concentration of
1.2 g protein/l and incubated in triplicate in a 96-well clear-bottom plate
with the fluorogenic substrate acetyl-Trp-Glu-His-Asp-7-amino-4-methylcoumarin (Ac-WEHD-AMC; 10 M; Bachem) (Rano et al., 1997). Production of
fluorescent-free AMC, released by caspase-1 activity, was monitored over 60 min
at 37 C using a microplate fluorometer (Victor2 multilabel counter, PerkinElmer Life Sciences; excitation, 355 nm; emission, 460 nm). Specific contribution
of caspase-1 activity in each brain extract was determined by preincubating
parallel sample aliquots with the caspase-1 preferring inhibitor acetyl-Trp-GluHis-Asp-aldehyde (Ac-WEHD-CHO; 10 M; Bachem) (Garcia-Calvo et al.,
1998) for 10 min at 37 C prior to the addition of the caspase substrate; the
diVerence between the substrate cleavage activity in the absence and presence of
Ac-WEHD-CHO was regarded as specific caspase-1 activity. The increase in
fluorescence was linear for 40 min after addition of the fluorogenic substrate.
Data were analyzed by linear regression within the linear range of the enzymatic
reaction and the fluorescence units were converted to micromoles of AMC by
using a standard curve generated with free AMC (Calbiochem); the results were
expressed as micromoles of free AMC released per minute per milligram of
protein and reported as mean SEM.
156
AMANTEA et al.
H. STATISTICAL ANALYSIS
Data are expressed as mean SEM and statistical analysis performed by
ANOVA followed by Dunnett’s or Tukey’s post hoc tests using the Prism 3
program (GraphPAD Software for Science, San Diego, CA). DiVerences were
considered statistically significant when p < 0.05.
III. Results
In situ zymography revealed a considerable increase of total gelatinolytic
MMP activity in the brain of rats subjected to 2-h MCAo followed by 2-h
reperfusion (Fig. 1). This early increase in gelatinolytic activity was evident in
the brain areas supplied by the MCA, including the striatum (E and G) and the
periinfarct motor cortex (M and O) as compared to the corresponding regions of
sham-operated animals (A, C, I, and K). MMPs broadly colocalized with nuclear
DNA staining as shown by the merging of the in situ zymography signal with
propidium iodide staining (D, H, L, and P).
Consistent with these findings, gel zymography assay demonstrated that both
MMP-2 and MMP-9 levels were increased in the ipsilateral, ischemic cortex of
rats subjected to tMCAo, as compared to the contralateral, nonischemic hemisphere; whereas no diVerence was found in the cortical samples from shamoperated animals (Fig. 2A). As shown in Fig. 2B, enhanced gelatinolytic activity
corresponding to MMP-2 and MMP-9 was also observed in the striatum with less
significant changes in the hippocampus, a brain region only marginally aVected
by the ischemic insult produced by MCAo (Fig. 2B). On the basis of molecular
weight, MMP-9 increases predominantly in the dimeric (250-kDa band) and
latent (90- to 95-kDa band) ‘‘pro’’ forms, whereas enhanced levels of MMP-2 following ischemia/reperfusion occurred mainly in the active forms (65- to 67-kDa band).
The levels of MMP-9 were low, in comparison to MMP-2, in both ischemic and
nonischemic hemispheres and throughout the brain regions examined, as shown by
the weaker gelatinolytic bands on the zymography gels.
To determine whether administration of the broad spectrum MMP inhibitor,
GM6001, aVects brain gelatinolytic activity following brain ischemia, we performed gel zymography on striatal tissue samples from rats exposed to 2-h MCAo
followed by 2-h reperfusion. As shown in Fig. 3, intra-arterial administration of
GM6001 (5 g/rat) prevented the increase of MMP-2 and MMP-9 activity in the
striatum ipsilateral to the ischemic insult, otherwise observed after pretreatment
with the GM6001 negative, inactive, control.
Inhibition of MMPs by GM6001 resulted in a significant reduction of MCAoinduced brain damage as revealed 22 h after reperfusion by the TTC-staining
157
MMPS MODULATE IL-1 PRODUCTION IN BRAIN ISCHEMIA
In situ
zymography
B
C
Merged
D
Striatum
Sham
A
In situ
zymography
PI staining
F
G
97 mm
H
MCAo
E
97 mm
97 mm
300 mm
101.37 mm
300 mm
I
101.37 mm
K
L
Cortex
Sham
J
101.37 mm
300 mm
M
99.32 mm
99.32 mm
O
P
MCAo
N
99.32 mm
300 mm
98 mm
98 mm
98 mm
FIG. 1. Increased MMP gelatinolytic activity after transient focal cerebral ischemia. Typical in situ
zymography with the MMP fluorogenic substrate DQ-gelatin FITC showing the robust increase of
MMP gelatinolytic activity in the striatum (E and G) and cortex (M and O) after 2-h occlusion of MCA
followed by 2-h reperfusion compared with sham-operated control (A, C, I, and K). Activity appeared
as a green fluorescent product and developed after incubation of coronal sections (10-m in thickness)
with the fluorogenic substrate DQ-gelatin FITC (panels A, C, E, G, I, K, M, and O). In situ
zymography merged with nuclear DNA staining with propidium iodide (PI) dye (red plus green in
panels D, H, L, and P) shows that increased gelatinolytic activity (green fluorescence in panels G and
O) broadly colocalizes with DNA staining (red fluorescence in panels F and N) in ischemic striatum (H)
and cortex (P). Scale bar: 97–101 m in B–D, F, G, H, J, K, L, N, O, and P; 300 m in A, E, I, and M.
technique. As illustrated in Fig. 4, administration of GM6001 negative
control (GM Neg, 5 g/rat, i.a.), given 15 min before tMCAo, resulted in an
extensive brain damage, comparable to vehicle-treated control (data not shown),
involving the cortex and the striatum (infarct volume: 502.6 18.4 mm3); this
was significantly reduced by administration of 5 g of GM6001 (infarct volume:
158
AMANTEA et al.
A
B
Sham
C
Striat
tMCAo
I
C
C
I
Hipp
I
C
I
MMP-9 dimer
MMP-9 dimer
Pro-MMP-9
MMP-9
Pro-MMP-9
MMP-9
MMP-2
MMP-2
FIG. 2. Increased MMP-9 and MMP-2 after transient focal cerebral ischemia. (A) Typical gel
zymography of brain cortical homogenates, subjected to aYnity precipitation with gelatin-conjugated
Sepharose beads, after 2-h occlusion of MCA followed by 2-h reperfusion. Representative zymogram gel
showing elevation of MMP-9 and MMP-2 in the ipsilateral (I), ischemic side as compared to contralateral
(C), nonischemic side in a rat subjected to tMCAo but not in a sham-operated animal. (B) Typical gel
zymography of striatal and hippocampal brain homogenates, subjected to aYnity precipitation with
gelatin-conjugated Sepharose beads, after 2-h transient cerebral ischemia and 2-h reperfusion. Representative zymogram gel showing elevation of MMP-9 and MMP-2 in the ipsilateral (I), ischemic side as
compared to contralateral (C), nonischemic side.
GM Neg
C
I
GM6001
C
I
MMP-9 dimer
Pro-MMP-9
MMP-9
MMP-2
FIG. 3. GM6001 decreases MMP-9 and MMP-2 activity in the brain of rats subjected to transient
focal cerebral ischemia. Rats pretreated with the broad-spectrum metalloproteinase inhibitor,
GM6001 (5 g/rat i.a., 15 min before MCAo), but not with the inactive, negative control
of GM6001 (GM Neg; 5 g/rat i.a.), show decreased MMP-9 and MMP-2 activity after ischemia
(2-h MCAo followed by 2-h reperfusion) as assessed by gel zymography of brain striatal homogenates
subjected to aYnity precipitation with gelatin-conjugated Sepharose beads.
159
MMPS MODULATE IL-1 PRODUCTION IN BRAIN ISCHEMIA
A
GM Neg
GM6001
C
B
Infract volume (mm3)
Infract area (mm2)
75
50
25
0
600
400
***
200
0
0
1
2
3 4 5 6
Coronal slice
7
8
GM Neg
GM6001
(0.05 mg)
GM6001
(5 mg)
FIG. 4. GM6001 protects against brain damage after transient focal cerebral ischemia. (A) Histological evidence for GM6001-mediated neuroprotection against brain damage produced by tMCAo.
After 2-h MCA and 22-h reperfusion, eight consecutive coronal sections from each brain were cut at
2-mm intervals from the frontal pole and incubated in TTC, which stains viable tissue red but not
infracted areas. GM6001 or its negative control (GM Neg) were dissolved in DMSO and administered
(5 g/rat, 2-l injection volume) into the external carotid artery 15 min before MCAo. Quantification
of infarct area (B) and volume (C) by TTC staining revealed significant neuroprotection by GM6001
(5 g/rat) as compared to its negative control. Infarct volumes were determined after 2h MCAo
followed by 22-h reperfusion by summing the infarcted area of the eight TTC-stained sections and
multiplying by the interval thickness between sections. Values are expressed as mean SEM
and analyzed by ANOVA followed by Dunnett’s post hoc test (n ¼ 3 rats per experimental group).
*** denotes p < 0.001 versus GM Neg.
251.9 9.5 mm3, p < 0.001 vs GM Neg), whereas a lower dose (0.05 g) resulted
ineVective (infarct volume: 467.0 3.9 mm3).
Under our present experimental conditions, ELISA assay of IL-1 revealed
significantly increased cytokine levels in the ipsilateral cortex of rats subjected to
MCAo followed by 2-h reperfusion (Fig. 5A), whereas a less marked increase was
detected following 1-h reperfusion (data not shown). More importantly, cytokine
160
AMANTEA et al.
Contralateral
Ipsilateral
A
#
**
IL-1b
(pg/mg protein)
12.5
10.0
7.5
5.0
2.5
0.0
Sham
Caspase-1 activity
(mmol AMC/min/mg protein)
B
tMCAo
Contralateral
Ipsilateral
0.20
0.15
0.10
0.05
0.00
Sham
tMCAo
FIG. 5. Transient focal cerebral ischemia increases IL-1 levels but not caspase-1 activity in the
ischemic cortex of rat. (A) Immunoreactive IL-1 levels are increased in the ipsilateral (I), ischemic
cortex of rats (n ¼ 6) subjected to 2-h occlusion of MCA followed by 2-h reperfusion as compared to
sham-operated animals (n ¼ 4). Immunoreactive IL-1 levels were assayed in individual brain cortical
tissue samples by an established, rat specific, sandwich ELISA. IL-1 levels were corrected for protein
concentration and the results expressed as pg of IL-1 per milligram of protein. Data are expressed as
mean SEM (n ¼ 4–6 per group). The resulting means were evaluated statistically for diVerences
using ANOVA followed by Tukey-Kramer test for multiple comparisons. # denotes p < 0.05 versus
control, contralateral cortex (C); ** denote p < 0.01 versus sham (contralateral and ipsilateral).
(B) Caspase-1 activity does not increase in the ischemic cortex of rats subjected to transient occlusion
(2 h) of MCA followed by 2-h reperfusion. Caspase-1 activity was determined by measuring cleavage of
the fluorogenic substrate Ac-WEHD-AMC in individual cortical homogenates obtained from shamoperated and ischemic rats (n ¼ 4 per group). Data are expressed as micromoles of free AMC released
per minute per milligram of protein and reported as mean SEM.
production was not associated with enhanced caspase-1 activity as determined by
measuring cleavage of the fluorogenic substrate Ac-WEHD-AMC (Fig. 5B).
To evaluate whether the observed elevation MMPs activity could contribute
to IL-1 processing and maturation, we used a pharmacological approach. After
MMPS MODULATE IL-1 PRODUCTION IN BRAIN ISCHEMIA
161
pretreatment with the broad spectrum MMPs inhibitor, GM6001, IL-1 levels
measured in the cortex ipsilateral to the ischemic insult (2-h MCAo followed by
2-h reperfusion) were comparable with levels detected in the contralateral nonischemic brain tissue. By contrast, administration of GM6001 negative control did not
aVect the increase of IL-1 observed in the cortex ipsilateral to the ischemic insult
(Fig. 6A). Western blotting analysis confirmed that mature (17-kDa band) IL-1
levels were significantly reduced in the ischemic cortex from rats treated with
GM6001 as compared to GM6001 negative control (Fig. 6B). By contrast, pro-IL1 (33- to 31-kDa band) levels were not aVected by GM6001 treatment. Moreover,
we detected a strong band (about 28 kDa) corresponding to a cleavage product of the
33- to 31-kDa pro-IL-1 which was less intense in the cortex of rats treated with
GM6001 as compared to GM negative control (Fig. 6B).
IV. Discussion
Despite the numerous reports implicating IL-1 in the neurodegeneration
associated with ischemic insult, the role of caspase-1 in cytokine maturation following injury is still controversial. Here we demonstrate that IL-1 increases very early
following tMCAo and this appears to occur independently from caspase-1 activation. Interestingly, we found that inhibition of MMPs activity prevented cytokine
enhancement in the ischemic cortex, thus suggesting that MMPs might contribute to
the early IL-1 maturation following a transient ischemic insult.
The role of MMPs in the pathophysiology of ischemic stroke has been widely
investigated particularly regarding their ability to degrade the neurovascular
matrix, thus leading to BBB damage, hemorrhage, and anoikis-like cell death
triggered by disruption of cell-matrix homeostasis (see Cunningham et al., 2005;
Rosenberg, 2002). An early and progressive increase of MMP-9 expression has
been detected particularly in endothelial cells in the ischemic hemisphere following tMCAo (Planas et al., 2001; Zhao et al., 2006) and has been implicated in the
early stages of tissue injury produced by the ischemic insult (Romanic et al., 1998).
Although the involvement of MMP-2 during the early stages after stroke has been
questioned (Asahi et al., 2001a), there is evidence for a transient enhancement of
MMP-2 early after temporary ischemia, which has been suggested to contribute
to the eVects of reperfusion and to the early opening of the BBB (Planas et al.,
2001; Rosenberg et al., 1998). At later stages following tMCAo, a redistribution
of gelatinases in the neurovascular unit does occur, with a massive increase of
MMP-2 expression in microglia/macrophages (Planas et al., 2001; Rosenberg
et al., 2001) and MMP-9 in astrocytes and neurons (Zhao et al., 2006). The former
eVect has been suggested to facilitate migration of macrophages into the ischemic
lesion, whereas the latter might represent an endogenous mechanism involved in
162
AMANTEA et al.
A
B
GM Neg
Contralateral
Ipsilateral
IL-1b (pg/mg protein)
10.0
*
7.5
GM6001 Std
33 kDa
31 kDa
28 kDa
17 kDa
5.0
2.5
28 kDa
0.0
GM Neg
GM6001
17 kDa
b-actin
FIG. 6. GM6001 abrogates the increase of cortical IL-1 induced by tMCAo and reduces the
expression of pro-IL-1 cleavage products. (A) GM6001 (5 g/rat i.a.), but not the inactive form of the
metalloproteinase inhibitor, GM6001 negative control (GM Neg; 5 g/rat i.a.), abrogates increase of
cortical IL-1 levels in the ischemic cortex of rats undergone tMCAo (2h/2h reperfusion). Immunoreactive IL-1 levels were assayed in individual brain cortical tissue samples (n ¼ 3 per group) by an
established, rat specific, sandwich ELISA. IL-1 levels were corrected for protein concentration and
the results expressed as picograms of IL-1 per milligram of protein. Data are expressed as mean
SEM values (n ¼ 3 per group). The resulting means were evaluated statistically for diVerences using
ANOVA followed by Tukey-Kramer test for multiple comparisons. * denotes p < 0.05 versus
GM6001. (B) Pro-IL-1 immunoreactivity of ipsilateral, ischemic brain cortical homogenates obtained
from rats subjected to tMCAo (2 h plus 2 h reperfusion) and pretreated with GM6001 (5 g/rat i.a.) or
with its negative control (GM Neg; 5 g/rat i.a.) was assessed by Western blotting analysis using an
antibody specific for pro-IL-1. The antibody detected a strong band of about 28 kDa which has been
previously described as a cleavage product of the 33- to 31-kDa pro-IL-1, together with less intense
bands of 33 and 31 kDa and a band of 17 kDa corresponding to mature IL-1 as determined by the
use of recombinant mouse IL-1 employed as a standard (Std). As compared to animals pretreated
with the inactive form of GM6001, a reduction of the intensity of IL-1 is evident in the cortex of
GM6001-treated animals (upper panel in B) and this is associated to a reduction of the intensity of the
28-kDa cleavage product band as better shown in middle panel in B which represents the same gel as in
upper panel but at a lower exposure time.
the resolution phase. In fact, inhibition of MMP-9 between 7 and 14 days after
stroke has been reported to result in a substantial reduction in the number of
neurons and new vessels implicated in neurovascular remodeling (Zhao et al.,
2006). These findings underscore the complexity of MMPs activity during tissue
injury, ranging from detrimental eVects during the early phases after stroke to
beneficial roles at later stages (Yong, 2005).
MMPS MODULATE IL-1 PRODUCTION IN BRAIN ISCHEMIA
163
Here we demonstrate that increased gelatinolytic activity is detected in situ as
early as 2 h following reperfusion both in the cortex and striatum of rats exposed
to 2-h MCAo. This is confirmed by gel zymography revealing that active MMP-2,
as well as pro- and dimeric forms of MMP-9 are significantly increased in the
brain regions aVected by the ischemic insult. Previous studies have demonstrated
that latent MMP-9 (dimer and propeptide forms) levels increase after focal (Asahi
et al., 2000; Gu et al., 2002, 2005; Romanic et al., 1998; Rosenberg et al., 1996 ) and
global cerebral ischemia in rodents (Magnoni et al., 2004; Rivera et al., 2002).
Accordingly, here we observed a gelatinolytic band around 250 kDa, which
increases significantly following brain ischemia/reperfusion. Similar gelatinolytic
activity (200- to 250-kDa band) was reported in the hippocampus of rats subjected
to global brain ischemia (Rivera et al., 2002) and in the brain of mice treated with
LPS (Pagenstecher et al., 2000). These high-molecular-weight bands may correspond to homodimers produced intracellularly during the maturation process of
the enzyme or to complexes of dimerized MMP-9, favored by increases in the
gelatinase B/TIMP-1 ratio (Dubois et al., 1998; Goldberg et al., 1992), or to
complexes of gelatinase B and integrins (Brooks et al., 1996).
It is widely accepted that uncontrolled expression of MMPs may result in
tissue damage and inflammation, though the mechanisms involved are still poorly
understood, especially concerning those leading to neuronal cell death. Activated
MMP-9 has been demonstrated to directly induce neuronal apoptosis both in vitro
and in vivo after focal cerebral ischemia/reperfusion (Gu et al., 2002). Some studies
have suggested that MMP-9 contributes to neuronal cell death via proteolysis
of basement membrane proteins, including laminin (Asahi et al., 2001b;
Castellanos et al., 2003; Chen et al., 2003; Gu et al., 2005; Horstmann et al.,
2003). MMPs are also related to activation and release of several bioactive
molecules such as cytokines, chemokines, and growth factors (see Parks et al.,
2004). Here we suggest that brain tissue damage produced by MMPs in the
ischemic brain might be linked to cleavage and activation of neuroinflammatory
mediators. In fact, increased gelatinolytic activity is associated with a rise of
mature IL-1 production in the ischemic cortex and, most importantly, inhibition
of MMPs activity by GM6001 prevents the early increase of IL-1 yielded by the
ischemic insult in the cortex and this results in significant neuroprotection.
There is in vitro evidence that MMPs activate pro-IL-1 proteolitically and
cleave the activated form of IL-1 to an inactive form, thereby providing both
positive and negative regulation (Ito et al., 1996; Schönbeck et al., 1998). Our results
extend these findings and suggest that MMPs contribute to maturation of IL-1 also
in vivo, under pathophysiological conditions such as brain ischemia, by a mechanism
independent from caspase-1 activation. Increased IL-1 generated via mechanisms
other than caspase-1 has also been reported in the brain of rats exposed to kainic
acid or 3,4-methylenedioxymethamphetamine (Eriksson et al., 1999; O’Shea
et al., 2005) and in an animal model of neuroAIDS (Corasaniti et al., 2005),
164
AMANTEA et al.
further emphasizing that, under certain circumstances, cytokine activation might
involve proteases other than caspase-1 (Fantuzzi et al., 1997).
Although ICE has been strongly implicated in the development of ischemic
brain damage (Hara et al., 1997a,b; Schielke et al., 1998; Yang et al., 1999), we
failed to detect increase in caspase-1 activity during the early stages after reperfusion. In animal models of MCAo, there is evidence that caspase-1 activity is
enhanced shortly after the induction of ischemia (Benchoua et al., 2001) and ICElike protease activity increases few hours after reperfusion (Hara et al., 1997a).
Nevertheless, some studies have revealed that caspase-1 displays a biphasic
activation after the ischemic insult (Benchoua et al., 2001), whereas others have
failed to detect any change in the expression of ICE after permanent MCAo
(Asahi et al., 1997). Therefore, we cannot exclude that under our experimental
conditions caspase-1 may be activated at some stage following tMCAo, thus
contributing to tissue damage through mechanisms that do not necessarily involve
IL-1 production. In fact, caspase-1 is able to directly process pro-caspase-3 to its
active form (Tewari et al., 1995), and it is also involved in the processing of IL-18
(Akita et al., 1997). Moreover, there is evidence that caspase-1 is an apical caspase
in neuronal cell death pathways, being involved in Bid cleavage and caspase-3
activation following an ischemic insult (Benchoua et al., 2001; Zhang et al., 2003b).
In conclusion, our data suggest that early production of IL-1 following
ischemic stroke is not associated with caspase-1 activation. By contrast, MMPs
appear to contribute to cytokine processing thus representing a crucial upstream
signal for the induction of neuroinflammatory responses. This strengthens the
involvement of MMPs in the development of tissue damage during the early
phases after stroke and emphasizes their potential as useful pharmacological
targets for the treatment of ischemia-induced neurodegeneration.
Acknowledgments
Partial finantial support from Italian Ministry of University and Research (PRIN prot.
2004053099_004 to G.B.) is gratefully acknowledged. Mr. Guido Fico is gratefully acknowledged for
skillful technical assistance.
References
Akita, K., Ohtsuki, T., Nukada, Y., Tanimoto, T., Namba, M., Okura, T., Takakura-Yamamoto, R.,
Torigoe, K., Gu, Y., Su, M. S., Fujii, M., Satoh-Itoh, M., et al. (1997). Involvement of caspase-1
and caspase-3 in the production and processing of mature human interleukin 18 in monocytic
THP.1 cells. J. Biol. Chem. 272, 26595–26603.
MMPS MODULATE IL-1 PRODUCTION IN BRAIN ISCHEMIA
165
Asahi, M., Asahi, K., Jung, J. C., del Zoppo, G. J., Fini, M. E., and Lo, E. H. (2000). Role for matrix
metalloproteinase 9 after focal cerebral ischemia: EVects of gene knockdown and enzyme inhibition with BB-94. J. Cereb. Blood Flow Metab. 20, 1681–1689.
Asahi, M., Hoshimaru, M., Uemura, Y., Tokime, T., Kojima, M., Ohtsuka, T., Matsuura, N., Aoki, T.,
Shibahara, K., and Kikuchi, H. (1997). Expression of interleukin-1 beta converting enzyme gene
family and bcl-2 gene family in the rat brain following permanent occlusion of the middle cerebral
artery. J. Cereb. Blood Flow Metab. 17, 11–18.
Asahi, M., Sumii, T., Fini, M. E., Itohara, S., and Lo, E. H. (2001a). Matrix metalloproteinase 2 gene
knockout has no eVect on acute brain injury after focal ischemia. Neuroreport 12, 3003–3007.
Asahi, M., Wang, X., Mori, T., Sumii, T., Jung, J. C., Moskowitz, M. A., Fini, M. E., and Lo, E. H.
(2001b). EVects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain
barrier and white matter components after cerebral ischemia. J. Neurosci. 21, 7724–7732.
Benchoua, A., Guegan, C., Couriaud, C., Hosseini, H., Sampaio, N., Morin, D., and Onteniente, B.
(2001). Specific caspase pathways are activated in the two stages of cerebral infarction. J. Neurosci.
21, 7127–7134.
Black, R. A., Kronheim, S. R., Cantrell, M., Deeley, M. C., March, C. J., Prickett, K. S., Wignall, J.,
Conlon, P. J., Cosman, D., Hopp, T. P., and Mochizuki, D. Y. (1988). Generation of biologically
active interleukin-1 by proteolytic cleavage of the inactive precursor. J. Biol. Chem. 263, 9437–9442.
Brooks, P. C., Stromblad, S., Sanders, L. C., von Schalscha, T. L., Aimes, R. T., StetlerStevenson, W. G., Quigley, J. P., and Cheresh, D. A. (1996). Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 85,
683–693.
Buttini, M., Sauter, A., and Boddeke, H. (1994). Induction of interleukin-1beta mRNA after focal
ischemia in the rat. Mol. Brain Res. 23, 126–134.
Castellanos, M., Leira, R., Serena, J., Pumar, J. M., Lizasoain, I., Castillo, J., and Davalos, A. (2003).
Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic
stroke. Stroke 34, 40–46.
Chen, Z. L., Indyk, J. A., and Strickland, S. (2003). The hippocampal laminin matrix is dynamic and
critical for neuronal survival. Mol. Biol. Cell 14, 2665–2676.
Copin, J.-C., Goodyear, M. C., Gidday, J. M., Shah, A. R., Gascon, E., Dayer, A., Morel, D. M., and
Gasche, Y. (2005). Role of matrix metalloproteinases in apoptosis after transient focal cerebral
ischemia in rats and mice. Eur. J. Neurosci. 22, 1597–1608.
Corasaniti, M. T., Turano, P., Bilotta, A., Malorni, W., Stringaro, A. R., Nisticò, R., Finazzi-Agrò, A.,
and Bagetta, G. (2001). Evidence that increases of mitochondrial immunoreactive IL-1 by HIV-1
gp120 implicate in situ cleavage of pro-IL-1 in the neocortex of rat. J. Neurochem. 78, 611–618.
Corasaniti, M. T., Russo, R., Amantea, D., Gliozzi, M., Siviglia, E., Stringaro, A. R., Malori, W.,
Melino, G., and Bagetta, G. (2005). Neuroprotection by the caspase-1 inhibitor Ac-YVAD(acyloxy)mk in experimental neuroAIDS is independent from IL-1 generation. Cell Death DiVer.
12, 999–1001.
Cunningham, L. A., Wetzel, M., and Rosenberg, G. A. (2005). Multiple roles for MMPs and TIMPs in
cerebral ischemia. Glia 50, 329–339.
Davies, C. A., Loddick, S. A., Toulmond, S., Stroemer, R. P., Hunt, J., and Rothwell, N. J. (1999). The
progression and topographic distribution of interleukin-1 beta expression after permanent middle
cerebral artery occlusion in the rat. J. Cereb. Blood Flow Metab. 19, 87–98.
Dubois, B., Peumans, W. J., Van Damme, E. J., Van Damme, J., and Opdenakker, G. (1998).
Regulation of gelatinase B (MMP-9) in leukocytes by plant lectins. FEBS Lett. 427, 275–278.
Eriksson, C., Van Dam, A. -M., Lucassen, P. J., Bol, J. G. J., Winblad, B., and Schultzberg, M. (1999).
Immunohistochemical localization of interleukin-1, interleukin-1 receptor antagonist and interleukin-1 converting enzyme/caspase-1 in the rat brain after peripheral administration of kainic
acid. Neuroscience 93, 915–930.
166
AMANTEA et al.
Fantuzzi, G., Ku, G., Harding, M. W., Livingston, D. J., Sipe, J. D., Kuida, K., Flavell, R. A., and
Dinarello, C. A. (1997). Response to local inflammation of IL-1-converting enzyme-deficient
mice. J. Immunol. 158, 1818–1824.
Friedlander, R. M., and Yuan, J. (1998). ICE, neuronal apoptosis and neurodegeneration. Cell Death
DiVer. 5, 823–831.
Garcia, J. H., Liu, K. F., and Relton, J. K. (1995). Interleukin-1 receptor antagonist decreases the number
of necrotic neurons in rats with middle cerebral artery occlusion. Am. J. Pathol. 147, 1477–1486.
Garcia-Calvo, M., Peterson, E. P., Leiting, B., Ruel, R., Nicholson, D. W., and Thornberry, N. A.
(1998). Inhibition of human caspases by peptide-based and macromolecular inhibitors. J. Biol.
Chem. 273, 32608–32613.
Gasche, Y., Copin, J. C., Sugawara, T., Fujimura, M., and Chan, P. H. (2001). Matrix metalloproteinase inhibition prevents oxidative stress associated blood-brain barrier disruption after transient
focal cerebral ischemia. J. Cereb. Blood Flow Metab. 21, 1393–1400.
Goldberg, G. I., Strongin, A., Coolier, I. E., Genrich, L. T., and Marmer, B. L. (1992). Interaction of
92-kDa type IV collagenase with the tissue inhibitor of metalloproteases prevents dimerization,
complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin.
J. Biol. Chem. 267, 4583–4591.
Gu, Z., Kaul, M., Yan, B., Kridel, S. J., Cui, J., Strongin, A., Smith, J. W., Liddington, R. C., and
Lipton, S. A. (2002). S-nitrosylation of matrix metalloproteinases: Signalling pathway to neuronal
cell death. Science 297, 1186–1190.
Gu, Z., Cui, J., Brown, S., Fridman, R., Mobashery, S., Strongin, A. Y., and Lipton, S. A. (2005).
A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and
neurons from apoptosis in transient focal cerebral ischemia. J. Neurosci. 25, 6401–6408.
Hagan, P., Poole, S., Bristow, A. F., Tilders, F., and Silverstein, F. S. (1996). Intracerebral NMDA
injection stimulates production of interleukin-1 in perinatal rat brain. J. Neurochem. 67,
2215–2218.
Hara, H., Fink, K., Endres, M., Friedlander, R. M., Gagliardini, V., Yuan, J., and Moskowitz, M. A.
(1997a). Attenuation of transient focal cerebral ischemic injury in transgenic mice expressing a
mutant ICE inhibitory protein. J. Cereb. Blood Flow Metab. 17, 370–375.
Hara, H., Friedlander, R. M., Gagliardini, V., Ayata, C., Fink, K., Huang, Z., Shimizu-Sasamata, M.,
Yuan, J., and Moskowitz, M. A. (1997b). Inhibition of interleukin 1 converting enzyme family
proteases reduces ischemic and excitotoxic neuronal damage. Proc. Natl. Acad. Sci. USA 94,
2007–2012.
Heo, J. H., Lucero, J., Abumiya, T., Koziol, J. A., Copeland, B. R., and del Zoppo, G. J. (1999). Matrix
metalloproteinases increase very early during experimental focal cerebral ischemia. J. Cereb. Blood
Flow Metab. 19, 624–633.
Horstmann, S., Kalb, P., Koziol, J., Gardner, H., and Wagner, S. (2003). Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: Influence of diVerent therapies. Stroke
34, 2165–2170.
Howard, A. D., Kostura, M. J., Thornberry, N., Ding, G. J. F., Limjuco, G., Weidner, J., Salley, J. P.,
Hogquist, K. A., Chaplin, D. D., Mumford, R. A., Schmidt, J. A., and Tocci, M. J. (1991).
IL-1-converting enzyme requires aspartic acid residues for processing of the IL-1 precursor at
two distinct sites and does not cleave 31-kDa IL-1. J. Immunol. 147, 2964–2969.
Ito, A., Mukaiyama, A., Itoh, Y., Nagase, H., Thøgersen, I. B., Enghild, J. J., Sasaguri, Y., and Mori, Y.
(1996). Degradation of interleukin 1 by matrix metalloproteinases. J. Biol. Chem. 271,
14657–14660.
Jourquin, J., Tremblay, E., Decanis, N., Charton, G., Hanessian, S., Chollet, A. M., Le Diguardjer, T.,
Khrestchatisky, M., and Rivera, S. (2003). Neuronal activity-dependent increase of net matrix
metalloproteinase activity is associated with MMP-9 neurotoxicity after kainate. Eur. J. Neurosci.
18, 1507–1517.
MMPS MODULATE IL-1 PRODUCTION IN BRAIN ISCHEMIA
167
Lee, R., Kermani, P., Teng, K. K., and Hempstead, B. L. (2001). Regulation of cell survival by secreted
proneurotrophins. Science 294, 1945–1948.
Legos, J. J., Whitmore, R. G., Erhardt, J. A., Parsons, A. A., Tuma, R. F., and Barone, F. C. (2000).
Quantitative changes in interleukin proteins following focal stroke in the rat. Neurosci. Lett. 282,
189–192.
Levy, D. E., Lapierre, F., Liang, W., Ye, Y., Lange, C. W., Li, X., Grobelny, D., Casabonne, M.,
Tyrrell, D., Holme, K., Nadzan, A., and Galardy, R. E. (1998). Matrix metalloproteinase
inhibitors: A structure-activity study. J. Med. Chem. 41, 199–223.
Li, H., Colbourne, F., Sun, P., Zhao, Z., Buchan, A. M., and Iadecola, C. (2000). Caspase inhibitors
reduce neuronal injury after focal but not global cerebral ischemia in rats. Stroke 31, 176–182.
Liu, T., McDonnell, P. C., Young, P. R., White, R. F., Siren, A. L., Hallenbeck, J. M., Barone, F. C.,
and Feurerstein, G. Z. (1993). Interleukin-1-beta messenger RNA expression in ischemic rat
cortex. Stroke 24, 1746–1751.
Longa, E. Z., Weinstein, P. R., Carlson, S., and Cummins, R. (1989). Reversible middle cerebral artery
occlusion without craniotomy in rats. Stroke 20, 84–91.
Magnoni, S., Baker, A., George, S. J., Duncan, W. C., Kerr, L. E., McCulloch, J., and Horsburgh, K.
(2004). DiVerential alterations in the expression and activity of matrix metalloproteinases 2 and 9
after transient cerebral ischemia in mice. Neurobiol. Dis. 17, 188–197.
Mulcahy, N., Ross, J., Rothwell, N. J., and Loddick, S. A. (2003). Delayed administration of interleukin-1
receptor antagonist protects against transient cerebral ischemia in the rat. Br. J. Pharmacol. 140,
471–476.
O’Shea, E., Sanchez, V., Orio, L., Escobedo, I., Green, A. R., and Colado, M. I. (2005). 3,4methylenedioxymethamphetamine increases prointerleukin-1 production and caspase-1 protease activity in frontal cortex, but not in hypothalamus, of Dark Agouti rats: Role of inteleukin-1
in neurotoxicity. Neuroscience 135, 1095–1105.
Pagenstecher, A., Stadler, A. K., Kincaid, C. L., Volk, B., and Campbell, I. L. (2000). Regulation of
matrix metalloproteinases and their inhibitor genes in lipopolysaccaride-induced endotoxemia in
mice. Am. J. Pathol. 157, 197–210.
Parks, W. C., Wilson, C. L., and Lopez-Boado, Y. S. (2004). Matrix metalloproteinases as modulators
of inflammation and innate immunity. Nat. Rev. Immunol. 4, 617–629.
Planas, A. M., Sole, A., and Justicia, C. (2001). Expression and activation of matrix metalloproteinase-2 and
-9 in rat brain after transient focal cerebral ischemia. Neurobiol. Dis. 8, 834–846.
RabuVetti, M., Sciorati, C., Tarozzo, G., Clementi, E., Manfredi, A. A., and Beltramo, M. (2000).
Inhibition of caspase-1-like activity by Ac-Tyr-Val-Ala-Asp-Chloromethyl ketone induces longlasting neuroprotection in cerebral ischemia through apoptosis reduction and decrease of proinflammatory cytokines. J. Neurosci. 20, 4398–4404.
Rano, T. A., Timkey, T., Peterson, E. P., Rotonda, J., Nicholson, D. W., Becker, J. W., Chapman, K. T.,
and Thornberry, N. A. (1997). A combinatorial approach for determining protease specificities:
Application to interleukin-1beta converting enzyme (ICE). Chem. Biol. 4, 149–155.
Relton, J. K., and Rothwell, N. J. (1992). Interleukin-1 receptor antagonist inhibits ischaemic and
excitotoxic neuronal damage in the rat. Brain Res. Bull. 29, 242–246.
Relton, J. K., Martin, D., Thompson, R. C., and Russell, D. A. (1996). Peripheral administration of
interleukin-1 receptor antagonist inhibits brain damage after focal cerebral ischemia in the rat.
Exp. Neurol. 138, 206–213.
Rivera, S., Ogier, C., Jourquin, J., Timsit, S., Szklarczyk, A. W., Miller, K., Gearing, A. J. H.,
Kaczmarek, L., and Khrestchatisky, M. (2002). Gelatinase B and TIMP-1 are regulated in a
cell- and time-dependent manner in association with neuronal death and glial reactivity after
global forebrain ischemia. Eur. J. Neurosci. 15, 19–32.
168
AMANTEA et al.
Romanic, A. M., White, R. F., Arleth, A. J., Ohlstein, E. H., and Barone, F. C. (1998). Matrix
metalloproteinase expression increases after cerebral focal ischemia in rats: Inhibition of matrix
metalloproteinase-9 reduces infarct size. Stroke 29, 1020–1030.
Rosell, A., Ortega-Aznar, A., Alvarez-Sabin, J., Fernandez-Cadenas, I., Ribo, M., Molina, C. A.,
Lo, E. H., and Montanter, J. (2006). Increased brain expression of matrix metalloproteinase-9
after ischemic and hemorrhagic human stroke. Stroke 37, 1399–1406.
Rosenberg, G. A. (2002). Matrix metalloproteinases in neuroinflammation. Glia 39, 279–291.
Rosenberg, G. A., Navratil, M., Barone, F., and Feuerstein, G. (1996). Proteolytic cascade enzymes
increase in focal cerebral ischemia in rat. J. Cereb. Blood Flow Metab. 16, 360–366.
Rosenberg, G. A., Estrada, E. Y., and DencoV, J. E. (1998). Matrix metalloproteinases and TIMPs
are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 29,
2189–2195.
Rosenberg, G. A., Cunningham, L. A., Wallace, J., Alexander, S., Estrada, E. Y., Grossetete, M.,
Razhagi, A., Miller, K., and Gearing, A. (2001). Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: Activation of MMP-9 linked to stromelysin-1 and
microglia in cell cultures. Brain Res. 893, 104–112.
Rothwell, N. (2003). Interleukin-1 and neuronal injury: Mechanisms, modification, and therapeutic
potential. Brain Behav. Immun. 17, 152–157.
Schielke, G. P., Yang, G. Y., Shivers, B. D., and Lorris Betz, A. (1998). Reduced ischemic brain injury
in interleukin-1 converting enzyme-deficient mice. J. Cereb. Blood Flow Metab. 18, 180–185.
Schönbeck, U., Mach, F., and Libby, P. (1998). Generation of biologically active IL-1 by matrix
metalloproteinases: A novel caspase-1-independent pathway of IL-1 processing. J. Immunol. 161,
3340–3346.
Sternlicht, M. D., and Werb, Z. (2001). How matrix metalloproteinases regulate cell behaviour. Annu.
Rev. Cell Dev. Biol. 17, 463–516.
Tewari, M., Quan, L. T., O’Rourke, K., Desnoyers, S., Zeng, Z., Beidler, D. R., Poirier, G. G.,
Salvesen, G. S., and Dixit, V. M. (1995). Yama/CPP32 beta, a mammalian homolg of CED-3, is a
CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81,
801–809.
Thornberry, N. A., Bull, H. G., Calaycay, J. R., Chapman, K. T., Howard, A. D., Kostura, M. J.,
Miller, D. K., Molineaux, S. M., Weidner, J. R., Aunins, J., Elliston, K. O., Ayala, J. M., et al.
(1992). A novel heterodimeric cysteine protease is required for interleukin-1 processing in
monocytes. Nature 356, 768–774.
Wang, X. K., Yue, T. L., Barone, F. C., White, R. F., Gagnon, R. C., and Feuerstein, G. Z. (1994).
Concomitant cortical expression of TNF- and IL-1 mRNAs follows early response gene
expression in transient focal ischemia. Mol. Chem. Neuropathol. 23, 103–114.
Wetzel, M., Rosenberg, G. A., and Cunningham, L. A. (2003). Tissue inhibitor of metalloproteinase-3
and matrix metalloproteinase-3 regulate neuronal sensitivity to doxorubicin-induced apoptosis.
Eur. J. Neurosci. 18, 1050–1060.
Yamasaki, Y., Matsuura, N., Shizuhara, H., Onodera, H., and Itoyama, Y. K. K. (1995). Interleukin-1
as a pathogenetic mediator of ischemic brain damage in the rats. Stroke 26, 676–681.
Yang, G. Y., Schielke, G. P., Gong, C., Mao, Y., Ge, H. L., Liu, X. H., and Betz, A. L. (1999).
Expression of tumor necrosis factor-alpha and intercellular adhesion molecule-1 after focal
cerebral ischemia in interleukin-1 converting enzyme deficient mice. J. Cereb. Blood Flow Metab.
19, 1109–1117.
Yong, V. W. (2005). Metalloproteinases: Mediators of pathology and regeneration in the CNS. Nat. Rev.
Neurosci. 6, 931–944.
Zhang, Z., Chopp, M., Goussev, A., and Powers, C. (1998). Cerebral vessels express interleukin 1 beta
after focal cerebral ischemia. Brain Res. 784, 210–217.
MMPS MODULATE IL-1 PRODUCTION IN BRAIN ISCHEMIA
169
Zhang, K., McQuibban, G. A., Silva, C., Butler, G. S., Johnston, J. B., Holden, J., Clark-Lewis, I.,
Overall, C. M., and Power, C. (2003a). HIV-induced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neurodegeneration. Nat. Neurosci. 6, 1064–1071.
Zhang, W. H., Wang, X., Narayanan, M., Zhang, Y., Huo, C., Reed, J. C., and Friedlander, R. M.
(2003b). Fundamental role of the Rip2/caspase-1 pathway in hypoxia and ischemia-induced
neuronal cell death. Proc. Natl. Acad. Sci. USA 100, 16012–7.
Zhao, B.-Q., Wang, S., Kim, H.-Y., Storrie, H., Rosen, B. R., Mooney, D. J., Wang, X., and Lo, E. H.
(2006). Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat. Med. 12,
441–445.